|   In the News

Synlogic Lands $80M from Ginkgo to Ramp Up “Living Medicines” R&D


Synlogic, a developer of so-called “living medicines” comprised of engineered bacteria, is teaming up with synthetic biology company Ginkgo Bioworks in an effort to advance drug candidates to human testing more quickly.

Read more.